PTC Therapeutics presents 2026 total revenue guidance of $1.29 billion-$1.32 billion
PTCT•PTC Therapeutics projected 2026 total revenue of $1.29 billion-$1.32 billion and operating expenses of $680 million-$720 million. It also reported $2.1 billion in cash and said it targets cash flow breakeven this year.
1. 2026 outlook
PTC Therapeutics projected 2026 total revenue of $1.29 billion-$1.32 billion, including product revenue of $960 million-$990 million, representing 64%-69% year-over-year growth. The company forecast operating expenses of $680 million-$720 million.
2. Launch and pipeline
Sephience generated $458 million in global revenue year to date during its first full launch year. PTC Therapeutics had $2.1 billion in cash and targeted cash flow breakeven for the year. The company expects to complete its application for accelerated approval of ST-920 gene therapy for Fabry disease in the fourth quarter.
